Osteoporosis Treatment Market is estimated to be US\$ 17.68 billion by 2030 with a CAGR of 4.3% during the forecast period

Osteoporosis Treatment Market accounted for US\$ 11.60 billion in 2020 and is estimated to be US\$ 17.68 billion by 2030 and is anticipated to register a CAGR of 4.3%. Osteoporosis is a condition in which body loses too much bone and there is an increase in bone weakness. The individual suffering from osteoporosis is more exposed to bone fractures. Hence, a proper treatment is required to cure and avoid the chances of complications. Osteoporosis, or thinning bones, can result in painful fractures. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

The report "Global Osteoporosis Treatment Market By Drugs Type (Selective Estrogen Receptor Modulators (SERMs), Rank Ligand (RANKL) Inhibitor, Calcitonin, Hormone Therapy, Parathyroid Hormone-Related Protein (PTHrP) Analog, and Bisphosphonates (Risedronate, Alendronate, Ibandronate, Zoledronic Acid, And Others)), By Route of Administration (Injectable, Oral, and Others), By Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospitals Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030"

Key Highlights:

- In 2019, FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. The U.S. Food and Drug Administration approved Evenity (romosozumabaqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture).
- In 2021, Leucadia Pharmaceuticals, a U.S. leader in generic injectables and the commercial arm of Custopharm, Inc., announced the launch of its latest FDA-approved generic, Calcitonin Salmon Injection, USP, Synthetic.

Analyst View:

Increasing rate and incidence of osteoporosis is expected to be a major factor which will boost the demand for its treatment products in market in upcoming time period. For instance, as per the International Osteoporosis Foundation, around 75 million people in Europe, U.S. and Japanare suffering from osteoporosis. Geriatric population is more exposed to osteoporosis diseases. Hence, the increasing rates of geriatric population are also expected to upsurge the demand for osteoporosis treatment products in upcoming period of time.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/108

Key Market Insights from the report:

The Global Osteoporosis Treatment Market accounted for US\$ 11.60 billion in 2020 and is estimated to be US\$ 17.68 billion by 2030 and is anticipated to register a CAGR of 4.3%. The global osteoporosis treatment market has been segmented on the basis of drug type, route of administration, distribution channel, and region.

- By Drug Type, the Global Osteoporosis Treatment Market is segmented into selective estrogen receptor modulators (SERMs), rank ligand (RANKL) inhibitor, calcitonin, hormone therapy, parathyroid hormone-related protein (PTHrP) analog, and bisphosphonates (risedronate, alendronate, ibandronate, zoledronic acid, and others.
- By Route of Administration, the Global Osteoporosis Treatment Market is segmented into injectable, oral and others.
- By Distribution Channel, the Global Osteoporosis Treatment Market is segmented into retail pharmacies, online pharmacies, and hospitals pharmacies.
- By region, the Global Osteoporosis Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account major market share as compared to that of other regions.

Competitive Landscape:

Key players operating in the global osteoporosis treatment market includes, GlaxoSmithKline Plc., Pfizer Inc., Daiichi Sankyo Company, Limited, Dr. Reddy\'s Laboratories, Mylan Inc., Pfenex Inc., Eli Lilly and Company, Asahi Kasei Corporation, F.Hoffmann La Roche, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co AG, Allergan plc., andAmgen Inc., and Teva Pharmaceutical Industries Ltd.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, subsegments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

Other topics:

https://www.prophecymarketinsights.com/market_insight/Global-Next-Generation-Cancer-Diagnostics-Market-4748

https://www.prophecymarketinsights.com/market_insight/Global-4D-Printing-in-Healthcare-Market-4263